TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00293202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hemodialysis patients will receive Saline by subcutaneous injection twice a week
Study: NCT02376530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Price Changes
Description: Price changes will be present during shopping session.
Study: NCT02620215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Ripening Balloon
Description: Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
Study: NCT01748110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Fitness Intervention
Description: This intervention will involve adhering to health interventions such as behavior and diet modification, and exercise. Patients will follow-up monthly with a health counselor to verify progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRIMM
Description: text message intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRIMM
Description: text message intervention.
Study: NCT03611972

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage
Description: Sugar-sweetened koolaid-flavored water.
Study: NCT02620215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostin
Description: Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
Study: NCT03074539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: Patients will be treated with Riociguat according to guidelines (2015 ERS/ESC guidelines for the diagnosis and treatment of pulmonary hypertension) and manufacturers recommendation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Endarteriectomy
Description: Patients will receive Pulmonary Endarteriectomy if they are suitable for this procedure according to the recommendation of the local CTEPH board. Patients must also consent to this surgical procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ballon Pulmonary Angioplasty
Description: Patients will receive Ballon Pulmonary Angioplasty if they are suitable for this procedure according to the recommendation of the local CTEPH board (e.g. not suitable for PEA). Patients must also consent to this procedure.The BPA will be accomplished in several interventions.
Study: NCT01023295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosbretabulin
Description: single dose, intravenous infusion
Study: NCT03261921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine is an alpha 2 agonist which has sedative ,analgesic, opioid sparing effect and was proved to prolong the duration of postoperative analgesia when added to local anesthetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine is an alpha 2 agonist which has sedative ,analgesic, opioid sparing effect and was proved to prolong the duration of postoperative analgesia when added to local anesthetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: local anesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: local anesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: local anesthetic agent
Study: NCT04000061

Intervention type: OTHER
Intervention: medical chart review
Description: data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations

Intervention type: OTHER
Intervention: medical chart review
Description: data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations

Intervention type: OTHER
Intervention: data generated by direct IT export
Description: data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data

Intervention type: OTHER
Intervention: data generated by direct IT export
Description: data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
Study: NCT00953706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT03351348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient-reported pain scores
Description: Will be recorded by the nurse in the PACU as per usual practice. Patients will be given a follow-up Brief Pain Inventory (short form) 6 months and 1 year after surgery to assess their level of chronic pain. Patients may be discharged when table either on the day of surgery or post-operative day 1 (on pill diary for same-day discharge patients).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient-reported pain scores
Description: Will be recorded by the nurse in the PACU as per usual practice. Patients will be given a follow-up Brief Pain Inventory (short form) 6 months and 1 year after surgery to assess their level of chronic pain. Patients may be discharged when table either on the day of surgery or post-operative day 1 (on pill diary for same-day discharge patients).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 ± 30 minutes hours postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
Study: NCT03549780

Intervention type: DEVICE
Group type: OTHER
Intervention: Stomal Occlusion Device
Description: Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
Study: NCT01786590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: Currently EBUS-TBNA is performed in patients with CT and/or PET positive lymph nodes in the mediastinum or hilum. In this study, all patients being considered for SBRT will undergo EBUS-TBNA for the lymph node staging prior to SBRT.
Study: NCT03015285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: A type of talk therapy called cognitive behaviour therapy (CBT) will be delivered to both groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy
Description: A type of talk therapy called cognitive behaviour therapy (CBT) will be delivered to both groups.
Study: NCT03427021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Infusion
Study: NCT03557411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
Study: NCT01589055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nicotine
Description: Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nicotine
Description: Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nicotine
Description: Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.
Study: NCT00156299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: choline magnesium trisalicylate
Description: 1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.
Study: NCT01922830

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-25 (Supherb)
Description: The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Bio-25, Supherb)
Description: A pill manufactured to mimic Bio-25 (Supherb) pill
Study: NCT05086354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JUMP
Description: Warm-up, stretching, jumping rope, cool-down
Study: NCT02278627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual lymphatic drainage
Study: NCT02537483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-120 Gel
Description: Investigational Product: IDP-120 Gel
Study: NCT00156299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: choline magnesium trisalicylate
Description: 1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.
Study: NCT03475576

Intervention type: OTHER
Group type: OTHER
Intervention: Keuzewijzer
Description: The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian. The most important value of this intervention is the approachability and the structured, but adjusted manner of support, focused on the individual context of care with their specific needs.~The 'Keuzewijzer' is an online tool whereby, in conversation with the informal care group and older civilian, the following aspects will be discussed in the context of the care for the older civilian: 1) analyzing the problem, 2) detection of possibilities or alternatives, 3) clarifying of motives and feelings and 4) weighting between values.
Study: NCT01217190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron (ODFS)
Description: Test Article

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron (ODFS)
Description: Test Article

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran (ODT)
Description: Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran (ODT)
Description: Comparator
Study: NCT03948672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CleanHands System
Description: All participants who regularly access the ICUs will wear the CleanHands system wristband while at work for 5 months and the reminding functionality is turned on.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CleanHands System
Description: All participants who regularly access the ICUs will wear the CleanHands system wristband while at work for 5 months and the reminding functionality is turned on.
Study: NCT01023295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosbretabulin
Description: single dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosbretabulin
Description: single dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosbretabulin
Description: single dose, intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: single dose, intravenous infusion
Study: NCT00430950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets
Description: olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks
Study: NCT03357081

Intervention type: DRUG
Intervention: CEUS or Contrast enhanced Ultrasound
Description: Real time contrast enhanced ultrasound with Lumason. CEUS or Contrast enhanced Ultrasound
Study: NCT03734887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Feedback
Description: Social networks are cost-free and highly influential social relationships and interactions that influence behavior and conversely are influenced by a patient's behavior. In addition to receiving a private text message regarding their medication adherence rate, participant's feedback will also be shared to a loved-one or friend that the participant is willing to share medical information with.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Private Feedback
Description: Participant will receive medication adherence feedback from a pharmacist at the start of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Private Feedback
Description: Participant will receive medication adherence feedback from a pharmacist at the start of the study.
Study: NCT03365544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Groups will be required to only ingest calories in their designated 8 hour eating window.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Groups will be required to only ingest calories in their designated 8 hour eating window.
Study: NCT03304028

Intervention type: DEVICE
Group type: OTHER
Intervention: Connected Devices for 3 months
Description: Inclusion will be proposed at a follow-up visit by the child's or adult's referring doctor. A written informed consent form will be obtained. Quality of Life and Anxiety-Depression will be collected. Then, each included patient will be equipped with CDs-spirometer, oxymeter, scale and watch during 3 months for base-line.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educationnal Intervention
Description: After a first statistical analysis and interpretation (5 months), alert parameters for each patient are then fixed. An educational visit will be scheduled with patients and a personnalized action plan will be defined..

Intervention type: DEVICE
Group type: OTHER
Intervention: Connected Devices for 12 months
Description: Each included patient will be re-equipped with CDs-spirometer, oxymeter, scale and watch during 12 months. If alerts occur, patients will be informed by email or SMS, with data transmission to the medical team who will not interfere. Patients should apply the shared action plan they learned. Quality of Life and Anxiety-Depression will be collected.

Intervention type: OTHER
Group type: OTHER
Intervention: Interviews
Description: At the end, semi-structured interviews will be completed to explore confidence on the CDs, impact on the doctor-patient relationship, change in the workload of medical team...etc.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Refusal Questionnaires
Description: Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal
Study: NCT03823235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human embryo culture
Description: humidifed or dry incubator
Study: NCT00949689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for insomnia and depression
Description: Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for insomnia and depression
Description: Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.
Study: NCT03257150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation
Description: Irreversible electroporation (IRE) is a process that uses the NanoKnife system to sent electrical currents to a cancer tumor which will disrupt the tumor cell and therefore causing the cell to die. Eligible patients will undergo in situ IRE performed via laparotomy surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife System
Description: A system consisting of electrode probes connected to a machine. The probes will be surgically placed around the tumor.
Study: NCT01918631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir disoproxil fumarate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Study: NCT03558555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen IV Soln
Description: 1000mg of IV acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Acetaminophen
Description: oral acetaminophen 975mg pills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Pills
Description: placebo match to acetaminophen
Study: NCT02963402

Intervention type: DRUG
Intervention: Tocilizumab

Intervention type: DRUG
Intervention: Adalimumab
Study: NCT03674502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADU-1604
Description: anti-CTLA-4 monoclonal antibody
Study: NCT03097588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant
Description: 300 mg, Given PO, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron Hydrochloride
Description: 0.5 mg, Given PO, QD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03748394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work-directed rehabilitation
Description: Each participant starts with a meeting together with an occupational therapist or a physical therapist, focusing on the participant's resources and obstacles for functioning well at work. A plan is designed and carried out over 8 weeks, including 1-4 different treatment modules of occupational and physical therapy, to support the person's ability to function at work

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: In a meeting with a physical therapist, each participant receives advice on physical activity to support mental health, according to national recommendations. The participant is offered to train at a local gym during 8 weeks.
Study: NCT00208117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline (Zoloft)
Description: Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If adverse events occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin (Zocor)
Description: The placebo drug will be administered for 8 weeks. To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.